Top 10 Dividend Companies To Watch In Right Now

Top 10 Dividend Companies To Watch In Right Now: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:

• [By Ben Levisohn]

  Yesterday, Sanofi (SNY) got a boost when Regeneron (REGN) reported solid trial results for its anti-cholesterol drug alirocumab. Today, it’s getting a lift from a trial data on its dengue fever vaccine. Citigroup’s Peter Verdult and Andrew Baum explain:

  Reuters A pest control worker sprayed insecticide to help control the spread of dengue fever in Kuala Lumpur.

  The second large scale Ph III study conducted in Latin America demonstrated overall efficacy of 61% (42-78% across the four serotypes), and 80% reduction in the risk of hospitalization. Ph III data from a study in Asia was presented earlier this year showing 56% efficacy (35-72% across the four serotyeps), a 89% reduction in dengue hemorrhagic fever, and 67% reduction in the risk of hospitalization. FDA has mandated an efficacy hurdle of >25% for Dengue vaccine candidates seeking approval. Consequently we see regulatory risks for Sanofi's Dengue vaccine as low…

  We continue to argue Sanofi offers near term momentum. This is based on scope for pipeline expectations to rise (today's news on Dengue vaccine and recent PCSK9 data should help), coupled with an attractive valuation and earnings upside risk going into Q3. Sanofi trades at a >10% PE discount to the sect! or yet offers comparable growth (5YR EPS CAGR 10%). That said, we retain our Neutral rating as we have higher conviction on the LT fundamentals elsewhere in the sector, and remain concerned about the sustainability of growth for the diabetes franchise (>30% of profits) post 2017. Preferred Pharma plays include AstraZeneca (AZN), Bayer, Novo Nordisk (NVO) and UCB. Bristol-Myers Squibb (BMY) and Pfizer (PFE) are our preferred US plays.

  Shares of Sanofi have climbed 1.1% to $55.58 at 10:30 a.m., while Regenron has gained 0.8% to $362.32, AstraZeneca has advanced 1.1% to $75.43, NovoNordisk has risen 0.9% to $45.79, Bristol-Myers Squibb is unchanged at $50.58 and Pfizer is up 0.4% at $29.3

• [By WWW.DAILYFINANCE.COM]

  Paul Morris/Bloomberg/Getty Images There were plenty of winners and losers this week, with a fast food chain's attempt to offer healthier fare falling short and the world's largest networking equipment company letting pink slips fly. Here's a rundown of the week's smartest moves and biggest blunders. Satisfries -- Loser Burger King Worldwide (BKW) is giving up on trying to woo calorie counters. The burger chain is discontinuing Satisfies -- the crinkle-cut fries that contain 40 percent less fat and 30 percent fewer calories than McDonald's (MCD) signature spud sticks -- at most restaurants. Some franchisees will keep offering Satisfries, but the item didn't stick on its menu for much more than a year. Burger King claims that the item didn't sell well despite clearing roughly 100 million orders for the slightly less unhealthy fries. One can argue that Satisfries were doomed because of Burger King chose to charge more for an order than its traditional fries. Fast food joints are magnetic to folks looking to save money. Plus Burger King isn't a big draw to folks on a diet despite following rivals into salads. Monster Beverage (MNST) -- Winner Coca-Cola (KO) has struggled to make a dent in the energy drink market dominated by Red Bull and Monster, so it's be! tting on ! a winner. Coca-Cola is investing $2.15 billion to buy a 16.7 percent stake in Monster Beverage. It's a smart move for Coca-Cola as it continues to diversify from carbonated drinks that have fallen out of favor with consumers. However, it's a bigger deal for Monster Beverage. The stock jumped on the news, and rightfully so. Green Mountain Coffee Roasters (GMCR) has soared since Coca-Cola made a similar investment earlier this year. Cisco (CSCO) -- Loser It's another round of pink slips at Cisco. The networking gear giant announced that it that it will be dismissing 6,000 workers or 8 percent of its staff. It's a big number, but the market shouldn't be surprised. This is the fourth summer in a row

• [By Johanna Bennett]

  Guess what? MannKind has found a partner. It announced a deal with Sanofi (SNY) early today, sending its stock climbing more than 20% in premarket action. Those gains got parsed, however, with the stock recently trading at $8.53, a 4.7% rise above Friday's closing price.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-dividend-companies-to-watch-in-right-now-3.html